Estrogen Receptor-beta Activated Apoptosis in Benign Hyperplasia and Cancer of the Prostate is Androgen Independent and TNFalpha Mediated

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2010 Feb 6

PMID 20133657

Citations 93

Authors

Stephen J McPherson

Shirin Hussain

Preetika Balanathan

Shelley L Hedwards

Birunthi Niranjan

Michael Grant

Upeksha P Chandrasiri

Roxanne Toivanen

Yuzhuo Wang

Renea A Taylor

Gail P Risbridger

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are androgen-dependent diseases commonly treated by inhibiting androgen action. However, androgen ablation or castration fail to target androgen-independent cells implicated in disease etiology and recurrence. Mechanistically different to castration, this study shows beneficial proapoptotic actions of estrogen receptor-beta (ERbeta) in BPH and PCa. ERbeta agonist induces apoptosis in prostatic stromal, luminal and castrate-resistant basal epithelial cells of estrogen-deficient aromatase knock-out mice. This occurs via extrinsic (caspase-8) pathways, without reducing serum hormones, and perturbs the regenerative capacity of the epithelium. TNFalpha knock-out mice fail to respond to ERbeta agonist, demonstrating the requirement for TNFalpha signaling. In human tissues, ERbeta agonist induces apoptosis in stroma and epithelium of xenografted BPH specimens, including in the CD133(+) enriched putative stem/progenitor cells isolated from BPH-1 cells in vitro. In PCa, ERbeta causes apoptosis in Gleason Grade 7 xenografted tissues and androgen-independent cells lines (PC3 and DU145) via caspase-8. These data provide evidence of the beneficial effects of ERbeta agonist on epithelium and stroma of BPH, as well as androgen-independent tumor cells implicated in recurrent disease. Our data are indicative of the therapeutic potential of ERbeta agonist for treatment of PCa and/or BPH with or without androgen withdrawal.

Citing Articles

An estrogen receptor β-targeted near-infrared probe for theranostic imaging of prostate cancer.

Dai J, Wu Y, Deng X, Zhou H, Dong C RSC Med Chem. 2025; .

PMID: 39867587 PMC: 11758099. DOI: 10.1039/d4md00767k.

Impact of Endocrine Disruptors on the Genitourinary Tract.

Caneparo C, Carignan L, Lonina E, Goulet S, Pellerin F, Chabaud S J Xenobiot. 2024; 14(4):1849-1888.

PMID: 39728407 PMC: 11676856. DOI: 10.3390/jox14040099.

The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.

Figueira M, Carvalho T, Macario-Monteiro J, Cardoso H, Correia S, Vaz C Biomedicines. 2024; 12(8).

PMID: 39200101 PMC: 11351860. DOI: 10.3390/biomedicines12081636.

Small molecule conjugates with selective estrogen receptor agonism promote anti-aging benefits in metabolism and skin recovery.

Zahr T, Boda V, Ge J, Yu L, Wu Z, Que J Acta Pharm Sin B. 2024; 14(5):2137-2152.

PMID: 38799642 PMC: 11119546. DOI: 10.1016/j.apsb.2024.01.014.

Enhanced prostatic Esr1 luminal epithelial cells in the absence of SRD5A2.

Sharkey C, Long X, Al-Faouri R, Strand D, Olumi A, Wang Z J Pathol. 2024; 263(3):300-314.

PMID: 38606616 PMC: 11166526. DOI: 10.1002/path.6283.

References

Jin Z, El-Deiry W . Overview of cell death signaling pathways. Cancer Biol Ther. 2005; 4(2):139-63. DOI: 10.4161/cbt.4.2.1508. View

McPherson S, Ellem S, Simpson E, Patchev V, Fritzemeier K, Risbridger G . Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology. 2006; 148(2):566-74. DOI: 10.1210/en.2006-0906. View

Hayward S, Rosen M, Cunha G . Stromal-epithelial interactions in the normal and neoplastic prostate. Br J Urol. 1997; 79 Suppl 2:18-26. DOI: 10.1111/j.1464-410x.1997.tb16917.x. View

Rijken A, Hu J, Perlman E, Morsberger L, Long P, Kern S . Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer. 1999; 26(3):185-91. View

Imamov O, Morani A, Shim G, Omoto Y, Thulin-Andersson C, Warner M . Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci U S A. 2004; 101(25):9375-80. PMC: 438984. DOI: 10.1073/pnas.0403041101. View

English H, Santen R, Isaacs J . Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate. 1987; 11(3):229-42. DOI: 10.1002/pros.2990110304. View

Collins A, Berry P, Hyde C, Stower M, Maitland N . Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23):10946-51. DOI: 10.1158/0008-5472.CAN-05-2018. View

Balanathan P, Ball E, Wang H, Harris S, Shelling A, Risbridger G . Epigenetic regulation of inhibin alpha-subunit gene in prostate cancer cell lines. J Mol Endocrinol. 2004; 32(1):55-67. DOI: 10.1677/jme.0.0320055. View

Jazbutyte V, Arias-Loza P, Hu K, Widder J, Govindaraj V, von Poser-Klein C . Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res. 2007; 77(4):774-81. DOI: 10.1093/cvr/cvm081. View

10.

Klotz L, McNeill I, Fleshner N . A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol. 1999; 161(1):169-72. View

11.

Vander Griend D, Karthaus W, Dalrymple S, Meeker A, DeMarzo A, Isaacs J . The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008; 68(23):9703-11. PMC: 3072758. DOI: 10.1158/0008-5472.CAN-08-3084. View

12.

Stone N, Clejan S . Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia. J Androl. 1991; 12(6):376-80. View

13.

McPherson S, Ellem S, Risbridger G . Estrogen-regulated development and differentiation of the prostate. Differentiation. 2008; 76(6):660-70. DOI: 10.1111/j.1432-0436.2008.00291.x. View

14.

Risbridger G, Wang H, Young P, Kurita T, Wang Y, Lubahn D . Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol. 2001; 229(2):432-42. DOI: 10.1006/dbio.2000.9994. View

15.

Seidlova-Wuttke D, Prelle K, Fritzemeier K, Wuttke W . Effects of estrogen receptor alpha- and beta-selective substances in the metaphysis of the tibia and on serum parameters of bone and fat tissue metabolism of ovariectomized rats. Bone. 2008; 43(5):849-55. DOI: 10.1016/j.bone.2008.07.237. View

16.

Leav I, Lau K, Adams J, McNeal J, Taplin M, Wang J . Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001; 159(1):79-92. PMC: 1850428. DOI: 10.1016/s0002-9440(10)61676-8. View

17.

Jarred R, McPherson S, Bianco J, Couse J, Korach K, Risbridger G . Prostate phenotypes in estrogen-modulated transgenic mice. Trends Endocrinol Metab. 2002; 13(4):163-8. DOI: 10.1016/s1043-2760(02)00575-1. View

18.

Ellem S, Risbridger G . Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer. 2007; 7(8):621-7. DOI: 10.1038/nrc2174. View

19.

Hillisch A, Peters O, Kosemund D, Muller G, Walter A, Elger W . Protein structure-based design, synthesis strategy and in vitro pharmacological characterization of estrogen receptor alpha and beta selective compounds. Ernst Schering Res Found Workshop. 2004; (46):47-62. DOI: 10.1007/978-3-662-05386-7_4. View

20.

Fisher C, Graves K, Parlow A, Simpson E . Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci U S A. 1998; 95(12):6965-70. PMC: 22703. DOI: 10.1073/pnas.95.12.6965. View